ERBB2 and breast carcinoma: The introduction of trastuzumab as a routine adjuvant treatment for patients with breast cancers that overexpress HER2 has already stretched the system (NICE, 2009a), and there is concern that the growth in adjuvant therapies across cancer care as a whole will put increasing pressure on chemotherapy day units.